Latest News
Featured News
Q&A with Scancell CMO Nermeen Varawalla
Could you tell us a bit about your background and what attracted you to Scancell? Given my educational background, which includes an MD in clinical medicine, DPhil (Oxon) in molecular medicine and INSEAD MBA, along with extensive leadership and clinical development...
Select the category
Interim Results and Business Update
Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma
Notice of Interim Results and Investor Presentation
Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+
Scancell to present positive Phase 2 data on Immunobody® iSCIB1+ in late-stage melanoma at SITC 2025
Results of 2025 Annual General Meeting
No results found.
Regulatory News Archive
JOIN OUR MAILING LIST
Sign up for news updates to stay up to date with Scancell.